{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-012199","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.794585+00:00","generated_at":"2026-06-06T07:04:58.697992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Viking Therapeutics reports Q4 net loss $24.6M, cash $362M; key trial data due 1Q24","bullets":["Net loss Q4 $24.6M ($0.25/sh) vs $19.6M ($0.26) YoY; full year loss $85.9M.","Cash & equivalents $362.1M vs $155.5M year-end 2022, funding pipeline milestones.","Phase 2 VENTURE (VK2735, obesity) topline results expected in 1Q24; oral VK2735 Phase 1 data also 1Q24.","Phase 2b VOYAGE (VK2809, NASH) 52-week histology results expected in 1H24.","Phase 1b VK0214 for X-ALD results expected in 1H24."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-012199","json":"https://secwatch.observer/filing/0000950170-24-012199.json","markdown":"https://secwatch.observer/filing/0000950170-24-012199.md","text":"https://secwatch.observer/filing/0000950170-24-012199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/0000950170-24-012199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/vktx-20240207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:04:58.697992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05077dcfeda22b85528a8b0770469cf391f34bac","claim":"Viking Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its clinical pipeline and other corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024012199/0000950170-24-012199-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}